Lamivudine Solution
Product Images NDC 57237-274

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Lamivudine (NDC 57237-274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Virologic Response Through Week 48, Epv20001a,b (intent-to-treat) (Lamivudine Figure1)

The image shows a graph titled "Figure 1. Virologic Response through Week 48, EPV200012.(Intent-to-Treat)" with two lines labeled "Lamivudine 150 mg twice daily" and "Lamivudine 300 mg once daily". The x-axis shows the treatment time in weeks ranging from 0 to 48, while the y-axis shows the proportion of subjects with HIV-1 RNA <400 copies/mL. The graph indicates that the group given Lamivudine 150 mg twice daily had a higher proportion of subjects with HIV-1 RNA <400 copies/mL over the 48 weeks.*

FDA Label Image

Package Label-principal Display Panel -10 mg/ml (240 mL Bottle Label) (Lamivudine Figure2)

This is an oral solution of Lamivudine, with each mL containing 10mg of the same. The usual dosage can be referred to by checking the package insert. It is advised to store the solution between temperatures 20°C to 25°C. The solution is distributed by Rising Health, LLC and was made in India. The packaging comes with a warning to keep the solution out of reach of children. The code printed on the packaging is TS/DRUGS/19/1993 while printing dotted lines are not to be printed.*

FDA Label Image

Chemical Structure (Lamivudine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.